TRIVASCULAR, INC. – Trademark Portfolio
Entity Type: 03
TRIVASCULAR, INC. holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 13 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include OVATION, CUSTOMSEAL, and TRIVASCULAR. The owner is based in SANTA ROSA, CA.
3910 BRICKWAY BOULEVARD
SANTA ROSA, CA 95403
Showing of trademarks Trademarks
Trademark Classifications
TRIVASCULAR, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does TRIVASCULAR, INC. have?
TRIVASCULAR, INC. has 15 U.S. trademarks filed with the USPTO. Of these, 4 registered, 6 abandoned, 5 cancelled.
What trademark classes does TRIVASCULAR, INC. file in?
TRIVASCULAR, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are TRIVASCULAR, INC.'s most well-known trademarks?
TRIVASCULAR, INC.'s registered trademark portfolio includes well-known marks such as OVATION, CUSTOMSEAL, and TRIVASCULAR. These are among 4 currently registered trademarks in the portfolio.
What is TRIVASCULAR, INC.'s trademark registration success rate?
TRIVASCULAR, INC. has a 27% trademark registration rate, with 4 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.